To read the full story, subscribe or sign in.

Vitalli Bio launches with $477M licensing deal with Daewoong for phase I-ready autoimmune disease candidate

May 2, 2023

Daewoong Pharmaceutical Co. Ltd. has out-licensed its phase I-ready autoimmune disease candidate, DWP-213388, to new spinout company Vitalli Bio in a deal worth up to $477 million.

BioWorld Asia Deals and M&A Immune Asia-Pacific

News in brief

BioWorld Asia

BioWorld Asia briefs for April 28, 2026

Chinese biotechs gain leverage as partners in dealmaking

BioWorld

China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...

AI generated image for researcher developing antisense oligonucleotides

Bio Korea 2026 kicks off with spotlight on oligonucleotides

BioWorld

Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...

AA meeting of minds as PTC, Novartis push votoplam in HD

BioWorld

What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...

University of Western Australia patents 5-HT2A/B modulators

BioWorld Science

University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...